These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29209711)

  • 21. FDA's Dunham delves into drug issues.
    Dunham B; Kahler SC
    J Am Vet Med Assoc; 2014 Apr; 244(7):762-3. PubMed ID: 24783315
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA shortened drug approval time in 1995.
    Public Health Rep; 1996; 111(4):290. PubMed ID: 8711090
    [No Abstract]   [Full Text] [Related]  

  • 23. Caution urged over the FDA's new breakthrough designation.
    Jiang K
    Nat Med; 2013 Oct; 19(10):1196. PubMed ID: 24100969
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
    Mostaghim SR; Gagne JJ; Kesselheim AS
    BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
    [No Abstract]   [Full Text] [Related]  

  • 25. Whatever happened to user fees and the FDA's promise to expedite new drug approvals?
    Gatty B
    Hosp Formul; 1993 Jul; 28(7):656, 655. PubMed ID: 10127048
    [No Abstract]   [Full Text] [Related]  

  • 26. Advisory committees" critical to the FDA's product review process.
    Rados C
    FDA Consum; 2004; 38(1):17-9. PubMed ID: 15032199
    [No Abstract]   [Full Text] [Related]  

  • 27. The FDA's new oncology office.
    Pazdur R
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):612-3. PubMed ID: 16167044
    [No Abstract]   [Full Text] [Related]  

  • 28. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 29. The FDA's defensive status and how it affects patient care.
    Yarows SA
    Arch Intern Med; 2011 Jul; 171(13):1217. PubMed ID: 21747025
    [No Abstract]   [Full Text] [Related]  

  • 30. Inappropriate obstructions to access: the FDA's handling of plan B.
    Wood SF
    Virtual Mentor; 2014 Apr; 16(4):295-301. PubMed ID: 24735580
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA's fraud policy and ethical concerns.
    Lepore P
    Qual Assur; 1995 Mar; 4(1):8-11. PubMed ID: 8520868
    [No Abstract]   [Full Text] [Related]  

  • 32. [FDA's new drug approval system].
    Ishii A
    Gan To Kagaku Ryoho; 1995 Aug; 22(9):1146-51. PubMed ID: 7661565
    [No Abstract]   [Full Text] [Related]  

  • 33. Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval.
    Kesselheim AS; Eddings W; Raj T; Campbell EG; Franklin JM; Ross KM; Fulchino LA; Avorn J; Gagne JJ
    PLoS One; 2016; 11(10):e0163339. PubMed ID: 27768700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving the FDA's advisory committee process.
    Brass EP; Hiatt WR
    J Clin Pharmacol; 2012 Aug; 52(8):1277-83. PubMed ID: 21908879
    [No Abstract]   [Full Text] [Related]  

  • 36. Accessing the accelerated approval pathway for rare disease therapeutics.
    Kakkis ED; Kowalcyk S; Bronstein MG
    Nat Biotechnol; 2016 Apr; 34(4):380-3. PubMed ID: 27054988
    [No Abstract]   [Full Text] [Related]  

  • 37. One hundred years of drug regulation: where do we go from here?
    Woosley RL
    Annu Rev Pharmacol Toxicol; 2013; 53():255-73. PubMed ID: 23072378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is FDA's revolving door open too wide?
    Piller C
    Science; 2018 Jul; 361(6397):21. PubMed ID: 29976809
    [No Abstract]   [Full Text] [Related]  

  • 39. The latest drugs on the FDA's radar.
    Waldron T
    Behav Healthc; 2006 Jun; 26(6):34-5. PubMed ID: 16833213
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA's role in administering the Hatch-Waxman Act.
    Malkin BJ
    Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.